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Summary
Although DNA damaging agents have revolutionized
chemotherapy against solid tumors, a narrow therapeu-
tic window combined with severe side effects has limited
their broader use. Here we show that RAD001 (everoli-
mus), a rapamycin derivative, dramatically enhances cis-
platin-induced apoptosis in wild-type p53, but not mutant
p53 tumor cells. The use of isogenic tumor cell lines ex-
pressing either wild-type mTOR cDNA or a mutant that
does not bind RAD001 demonstrates that the effects of
RAD001 are through inhibition of mTOR function. We fur-
ther show that RAD001 sensitizes cells to cisplatin by
inhibiting p53-induced p21 expression. Unexpectedly,
this effect is attributed to a small but significant inhibi-
tion of p21 translation combined with its short half-life.
These findings provide the molecular rationale for com-
bining DNA damaging agents with RAD001, showing that
a general effect on a major anabolic process may dra-
matically enhance the efficacy of an established drug
protocol in the treatment of cancer patients with solid
tumors.
Introduction
Metazoans have evolved elaborate mechanisms to
monitor genomic stability and to maintain the genetic
integrity of the organism (Khanna and Jackson, 2001;
Vousden and Lu, 2002). Amongst these are those that
rid the organism of genetically damaged cells, which
could give rise to neoplastic lesions (Khanna and Jack-
son, 2001; Vousden and Lu, 2002). The key molecular
component, which acts in response to DNA damage, is*Correspondence: heidi.lane@pharma.novartis.com (H.A.L.); gthomas@
fmi.ch (G.T.)
4 Present address: Genome Research Institute, University of Cincinnati,
2180 E. Galbraith Road, Cincinnati, Ohio 45237.the tumor suppressor p53 (Woods and Vousden, 2001).
DNA damage leads to the stabilization of p53 and the
activation of pathways which either arrest cell cycle
progression, allowing DNA repair if the damage is not
severe, or apoptosis if the damage is irreversible (El-
Deiry, 2003; Vousden and Lu, 2002). Importantly, many
tumor cells appear to be highly prone to apoptosis
(Weiss, 2003), which has been exploited clinically
through the use of DNA-damaging agents, such as cis-
platin. Cisplatin triggers apoptosis, especially in p53
wild-type tumor cells (Siddik, 2003), which represent
approximately half of all cancers (Soussi et al., 2000).
However, the difficulty with such agents is general tox-
icity combined with a narrow therapeutic window: too
low a dose has no effect, whereas too high a dose af-
fects all cells (El-Deiry, 2003; Khanna and Jackson,
2001; Weiss, 2003). Such factors contribute to the un-
der-dosing of patients and failure to blunt disease.
Thus, drugs which would sensitize DNA-damaging
agents toward apoptosis could increase their efficacy
in the clinic.
Rapamycin has been suggested as a potential che-
motherapeutic sensitizer (Shi et al., 1995). Rapamycin
is a fungicide produced by Streptomyces hygroscopi-
cus and forms an inhibitory complex with the immu-
nophilin FKBP12, which binds to and inhibits the
mammalian target of rapamycin (mTOR; Hay and So-
nenberg, 2004). mTOR belongs to the phosphatidyli-
nositide-3OH kinase (PI3K) related family of protein ki-
nases, including ataxia telangiectasia mutated protein
(ATM), ATM and RAD3 related protein (ATR) and DNA-
dependent protein kinase (DNA-PK), which are involved
in the DNA damage response (Keith and Schreiber,
1995; Khanna and Jackson, 2001). In contrast to the
other family members, mTOR appears to act by integ-
rating nutrient/energy signaling with that of growth
factor signaling (Dennis et al., 2001; Hay and Sonen-
berg, 2004). Growth factors modulate mTOR activity
through PI3K, which mediates protein kinase B (PKB)
activation and the phosphorylation and inactivation of
the tumor suppressor complex made up of tuberous
sclerosis complex proteins 1 and 2 (TSC1/TSC2;
Jaeschke et al., 2002; Marygold and Leevers, 2002).
TSC2 acts as a GTPase activating protein (GAP) toward
the Ras homolog, Ras homologue enriched in brain
(Rheb; Garami et al., 2003; Zhang et al., 2003). It is
thought that Rheb-GTP either acts on mTOR or influ-
ences mTOR’s signaling downstream to such effectors
as S6 ribosomal protein kinases (S6K1 and S6K2) or the
eukaryotic initiation factor 4E binding proteins (4E-BP1
through 3), leading to inhibition of translation (Hay and
Sonenberg, 2004).
Given the sensitivity of tumor cells to nutrients and
energy, we suggested that tumor cells might be more
sensitive than normal cells to rapamycin treatment
(Jaeschke et al., 2004). Indeed, early clinical trial results
in advanced cancer patients with the two rapamycin
derivatives, RAD001 and CCI-779, have demonstrated
promising antitumor activity with relatively minor toxic-
ity (Huang et al., 2003a; Panwalkar et al., 2004). More-
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748Figure 1. RAD001-Enhanced Cisplatin-Induced Apoptosis Is p53 Dependent
(A and B) A549 cells were treated for 24 hr with either DMSO or 20 nM RAD001 in combination with cisplatin. Proliferation rates and loss of
cell viability were measured using the YO-PRO assay (Experimental Procedures). Data represent the mean ± standard deviation of three
independent experiments (* = significant fold induction with p < 0.05; t tests and two-way ANOVA indicate that the interaction between
RAD001 and cisplatin was highly significant [p < 0.001]).
(C) A549 cells were treated for 24 hr with either DMSO or 20 nM RAD001 in combination with the indicated concentrations of cisplatin. The
expression levels of p53 and PARP were assessed by immunoblotting with indicated antibodies.
(D) A549 cells were untransfected or transfected with LacZ or p53 siRNAs (Experimental Procedures) and treated with the indicated doses of
cisplatin. Protein levels of p53, PARP, p21, and α-tubulin were assessed by Western blotting.over, rapamycins are well tolerated in transplantation, a
fwhere they are chronically employed (Dutcher, 2004).
Although under certain conditions rapamycins induce apoptosis, such as the extended withdrawal of serum
rom cultured cells, they generally act as cytostatic
gents (Huang et al., 2001). These observations raised
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for DNA-damaging agents.
Here, we investigated whether RAD001 enhances the
effect of DNA-damaging agents on loss of tumor cell
viability and if p53 plays a role in this process. Next, we
generated isogenic tumor cell lines expressing a mu-
tant of mTOR that no longer binds RAD001 to deter-
mine if the observed effects are mediated through inhi-
bition of mTOR. Finally, we used these tools with RNA
interference to identify the downstream target and
mechanism by which RAD001 enhances the effect of
cisplatin on apoptosis.
Results
RAD001 Enhances Cisplatin-Induced Apoptosis
An earlier report showed that rapamycin alone has little
effect on apoptosis but suggested it may enhance the
effects of cisplatin (Shi et al., 1995). To test this, the
effect of RAD001 and cisplatin on inhibition of cell pro-
liferation as well as loss of cell viability was examined
in A549 human nonsmall cell lung carcinoma cells. Con-
sistent with recent findings (Boulay et al., 2004), at a
concentration in 10-fold excess of its IC50 RAD001
caused a 30% inhibition of cell proliferation within 24
hr of treatment (Figure 1A), with cells accumulating in
G1 (data not shown). Similar inhibitory effects with cis-
platin alone required concentrations of 4 to 8 g/ml,
with the two drugs together having an additive inhibi-
tory effect within the relatively short exposure time (Fig-
ure 1A). Despite the pronounced effect of RAD001 on
cell proliferation, it had little effect on cell viability (Fig-
ure 1B), although it dramatically enhanced the effects
of increasing doses of cisplatin (p < 0.05) with a more
than 10-fold difference observed at 4 g/ml cisplatin, a
concentration where cisplatin alone had no detectable
effect (Figure 1B). Notably, the increased sensitivity
caused by RAD001 was abruptly lost at higher concen-
trations of cisplatin, falling to levels observed with cis-
platin alone (Figure 1B). Thus, the two drugs induce dis-
tinct responses, with RAD001 having a striking effect
on the loss of cell viability at suboptimal concentrations
of cisplatin.
Given that A549 cells are wild-type (wt) for p53, it was
reasoned that the apoptotic response was due to p53
activation. Consistent with this hypothesis, cisplatin alone
induced p53 and (ADP-ribose) polymerase (PARP) cleav-
age, as measured by the appearance of the PARP Mr
86,000 caspase 3 cleavage product. This effect, unlike
the induction of p53, was clearly enhanced by RAD001
(Figure 1C). In contrast, RAD001 alone had no effect
on either p53 induction or PARP cleavage (Figure 1C),
consistent with RAD001 having no effect on loss of cell
viability (Figure 1B). Similar results were obtained with
the DNA-damaging agent gemcitabine (data not shown).
That these effects were elicited through p53 was shown
by the fact that lowering p53 protein levels with a spe-
cific siRNA was paralleled by inhibition of cisplatin-
induced PARP cleavage (Figure 1D), cell proliferation,
and loss of cell viability (see Figure S1A in the Supple-
mental Data available with this article online). Moreover,
this was not due to an siRNA off target effect, as the
same result was obtained with two additional p53
siRNAs (Figure S1B). In contrast, a lactose permease(LacZ) siRNA had no effect on any of the three re-
sponses, including the induction of the cell cycle inhibi-
tor p21 (Figure 1D and Figure S1A), a p53 transcrip-
tional target (el-Deiry et al., 1993). The requirement for
wt p53 was confirmed in studies with a matched set of
p53+/+ and p53−/− MEFs where RAD001 only enhances
cisplatin-induced apoptosis in the p53+/+ MEFs (Figure
S2A). This conclusion was also supported by studies in
MCF7, PC3M, and DU145 tumor cell lines, which are
p53+/+, p53−/−, or p53 mutant, respectively. Only in MCF7
tumor cells did RAD001 enhance cisplatin-induced loss
of cell viability (Figure S2B). Taken together, the ability
of RAD001 to potentiate the loss of cell viability caused
by DNA damaging agents is p53 dependent.
RAD001-Resistant Cell Lines
The sensitizing effects of RAD001 on loss of cell viabil-
ity are presumed to be through inactivation of the
mTOR pathway. To test this, A549 isogenic cell lines
were generated that were either sensitive or resistant
to RAD001. Cells were stably transformed with a retro-
virus vector containing either a hemagglutinin (HA)-
tagged wt or rapamycin-resistant (RR) mTOR cDNA,
S2035T. The latter has no effect on mTOR-kinase activ-
ity but prevents FKBP12-rapamycin from binding to
mTOR (Hay and Sonenberg, 2004). Two wt (wt15 and
wt28) and two RAD001-resistant mutant (RR11 and
RR52) clones were selected, each expressing approxi-
mately equal levels of HA-tagged mTOR (Figures 2B
and 2C). All four cell lines expressed slightly higher
levels of total mTOR as compared to either the retrovi-
ral noninfected A549 parental cells or A549 cells in-
fected with the empty retroviral vector (Figures 2A–2C).
To test the inhibitory effect of RAD001 on the different
cell lines, the activity of mTOR was measured by as-
sessing the phosphorylation of S6K1 threonine 389
(S6K1 T-389), with a phosphospecific antibody, or 4E-
BP1 phosphorylation, by its electrophoretic mobility
(Figures 2A–2C). The results show that RAD001 inhibits
S6K1 T-389 phosphorylation in a concentration-depen-
dent manner in the cell lines expressing endogenous
wt mTOR (Figure 2A) or the ectopic wt cDNA (Figure
2B), whereas it was completely protected in the two RR
cell lines (Figure 2C). Similarly, 4E-BP1 phosphorylation
decreased, as judged by its increased electrophoretic
mobility as a function of increasing concentrations of
RAD001 in cells expressing either endogenous mTOR
or the ectopic wt cDNA (Figures 2A and 2B), but not in
cells expressing the RR cDNA (Figure 2C). Thus, the
S2035T mutation confers RAD001 resistance, as judged
by S6K1 and 4E-BP1 phosphorylation.
mTOR Required for Enhanced
Cisplatin-Induced Apoptosis
To determine whether the antiproliferative effects of
RAD001 on A549 cells were through inactivation of
mTOR, the effect of the drug was tested on the wt and
RR mTOR cell lines. The two wt mTOR lines exhibited
similar sensitivity to RAD001 as the parental or A549
cells infected with the empty retroviral vector, despite
their slightly elevated mTOR expression levels. In con-
trast, RAD001 had no significant effect on the prolifera-
tion rate of the RR cell lines (Figure 3A), even at con-
Cell
750Figure 2. Rapamycin-Resistant mTOR Protects A549 Cells from RAD001
(A) A549 cells infected with the empty retrovirus (pBabe Puro) or (B) a retrovirus encoding either hemagglutinin-tagged wild-type mTOR (wt)
or (C) HA-tagged rapamycin resistant mTOR (RR).
(A) A549 parental, pBabe Puro, (B) HA-mTOR wt clone 15 and 28, as well as (C) the RR clones 11 and 52 were exposed for 24 hr to DMSO,
0.2 nM or 20 nM RAD001. Cell lysates were analyzed by Western blot analysis.centrations up to 20 µM (Figure 3B). These findings t
asupport the argument that the sole antiproliferative
target of RAD001 in A549 cells is mTOR, as previously p
ldemonstrated in rhabdomyosarcoma cells (Huang et
al., 2001). Importantly, RAD001 alone had little effect on d
ccell viability of wt lines but strongly enhanced the effect
of cisplatin (Figure 3C). In contrast, the RR cell lines i
were resistant to RAD001 enhanced loss of cell viability 4
induced by cisplatin (Figure 3D). Thus, RAD001 sensiti- (
zation of p53 wild-type cells to DNA-damaging agents b
appears to be through inhibition of mTOR function. p
4
pRAD001 Inhibits Cisplatin-Induced p21 Induction
The question that arises from these studies is the s
bmechanism by which RAD001 sensitizes p53 wt tumorso DNA-damaging agents. A major target of the p53
ntiapoptotic branch of the DNA damage response is
21 (Gartel and Tyner, 2002). Induction of p21 by p53
eads to cell cycle arrest, allowing the potential for DNA
amage repair. Analysis of p21 protein levels in A549
ells following cisplatin treatment shows that the
ncrease in p21 is strongly inhibited by RAD001 (Figure
A). Similar results were also obtained for MCF7 cells
Figure 4B). At the concentrations of cisplatin used,
oth cell lines displayed no change in the levels of the
53-induced proapoptotic protein Bax (Figures 4A and
B), possibly reflecting the low doses of cisplatin ap-
lied (see below). These findings suggest that RAD001
ensitizes tumor cells to DNA-damaging agents by
locking the upregulation of p21 through inhibition of
RAD001 Sensitization of Cisplatin-Induced Apoptosis
751Figure 3. RAD001 Mediates Enhanced Sensitivity to Cisplatin through mTOR
(A) A549 parental, pBabe Puro, HA-mTOR wt (clone 15/28), and HA-mTOR RR (clone 11/52) cells were treated with either DMSO (black bars),
0.2 nM RAD001 (white bars), or 20 nM RAD001 (gray bars). After 4 days, cells were counted, and the data represent the mean ± standard
deviation of three independent experiments (* = significant inhibition with p < 0.05, one-way ANOVA).
(B) A549 HA-mTOR wt clones 15 (open circle)/28 (open diamond) and RR clones 11 (filled triangle)/52 (filled square) were treated with the
indicated concentration of RAD001. After 3 days, cell proliferation rates were assessed using the YO-PRO assay (Experimental Procedures)
and plotted as % of DMSO control-treated cells. Data represent the mean ± standard deviation of three independent experiments.
(C) A549 HA-mTOR wt28 cells and (D) A549 HA-mTOR RR52 cells were treated with the indicated concentrations of cisplatin in the presence
of DMSO (black bars) or 20 nM RAD001 (white bars). After 24 hr, cell viability was assessed using the YO-PRO-method. Data represent the
mean ± standard deviation of three independent experiments (* indicates statistically significant inhibition at p < 0.05, t tests and two-way
ANOVA indicates that the interaction between RAD001 and cisplatin was highly significant [p < 0.001]).mTOR. Consistent with this, cisplatin induces PARP
cleavage and increased p21 protein expression in wt28
and RR52 A549 cell lines (Figure 5); however, low doses
of cisplatin have no affect on PARP cleavage but clearly
induce p21 expression (Figures 5A and 5B). More strik-
ing, in the presence of RAD001, the wt28 cell line exhib-
ited enhanced cisplatin-induced PARP cleavage and
a reduction in p21 protein levels, effects completely
blunted in the mutant RR52 cell line (Figures 5A and
5B). These findings are consistent with analysis of loss
of cell viability (Figures 3C and 3D). These observations
favor inhibition of mTOR signaling as being responsible
for the reduced levels of p21 protein. Thus, the effects
of RAD001 on cell viability, PARP cleavage, and repres-
sion of p21 protein levels appear to be regulated
through mTOR.Enhanced Cisplatin-Induced Cell Death Is Due
to the Reduction of p21 Protein
The findings above argue that RAD001 enhances the
ability of cisplatin to induce cell death by inhibiting p53-
induced p21 expression, shifting the equilibrium of the
p53 response from cell repair toward apoptosis. Despite
this, the effect of RAD001 is lost at higher concentra-
tions of cisplatin (Figure 1B), suggesting that if inhibi-
tion of p21 is responsible for advancing the apoptotic
program, then this response should be altered at higher
concentrations of cisplatin. To test this possibility, A549
cells were treated with either 1 g/ml or 15 g/ml of
cisplatin for increasing times, and the induction of p53,
p21, and PARP cleavage was monitored. At low cis-
platin concentrations p53 was induced, followed by
p21, with no detectable PARP cleavage (Figure 6A). In
Cell
752Figure 4. RAD001 Inhibits Cisplatin-Induced
p21 Expression in A549 and MCF7 Cells
(A) A549 and (B) MCF7 cells were treated for
24 and 30 hr, respectively, with indicated
concentrations of cisplatin in the presence
of DMSO or 20 nM RAD001. Protein levels of
p21, Bax, and actin were assessed by West-
ern blotting.Figure 5. RR mTOR Protects Cisplatin-
Induced p21 Downregulation by RAD001
(A) A549 HA-mTOR wt28 cells or (B) A549
HA-mTOR RR52 cells were treated for 24 hr
with indicated concentrations of cisplatin in
the presence of DMSO or 20 nM RAD001.
PARP, p21, and actin protein levels were as-
sessed by Western blotting.
RAD001 Sensitization of Cisplatin-Induced Apoptosis
753Figure 6. Activation of p53-Dependent Anti-
and Proapoptotic Programs
(A) A549 cells treated with 1 or 15 µg/ml cis-
platin were incubated for the indicated
times. PARP, p53, p21, and actin protein
levels were assessed by Western blotting.
(B) A549 cells were untransfected or trans-
fected with 100 nM LacZ or p21siRNAs. After
30 hr, cells were treated for 24 hr with the
indicated concentrations of cisplatin. PARP,
p53, p21, and actin protein levels were as-
sessed by Western blotting.contrast, at the higher concentration, p53 induction
was more rapid and robust, with PARP cleavage being
detected at later time points (Figure 6A). However, de-
spite the strong induction of p53, there was no induc-
tion of p21. This is consistent with more severe DNA
damage caused by high cisplatin concentrations ab-
lating the p53-induced p21-antiapoptotic response.
That loss of p21 protein is responsible for RAD001-
enhanced cell death was shown by knocking down p21
protein with a targeted siRNA and inducing PARP
cleavage in A549 cells treated with low doses of cis-
platin (Figure 6B). Such treatment had no effect on p53
or actin protein levels (Figure 6B), nor did LacZ siRNA
have an effect on the level of any of the three proteins
(Figure 6B). Moreover, the siRNA knockdown of basal
p21 protein had no effect on PARP cleavage (Figure
6B). Thus, lowering p21 levels shifts the p53 response
at low concentrations of cisplatin from cell repair to
cell death.
RAD001 Reduces p21 Expression by Inhibiting
Global Translation
A question that arises from these studies is the mecha-
nism by which RAD001 blocks p21 protein expression.
As p21 protein has a short half-life (Bloom et al., 2003),
we first tested whether RAD001 accelerated this pro-
cess in cells treated with 0.5 g/ml of cisplatin by
blocking nascent translation with cycloheximide. Al-
though initial p21 protein levels in RAD001-treated cellswere reduced (Figure 7A, left panel), there was no ap-
parent difference in the half-life of p21 following cyclo-
heximide treatment (Figure 7A, right panel). In contrast,
neither RAD001 nor cycloheximide had an effect on
levels of actin protein, an abundant, stable cytoskeletal
component (Figure 7A). Analysis of p21 mRNA by
Northern blot analysis revealed that its levels, as well
as those of β-actin, were unaffected by RAD001 (Figure
7B). However, at higher concentrations of cisplatin, to-
tal p21 mRNA levels are diminished (see the Discus-
sion). Recently, others suggested that rapamycin selec-
tively inhibits mitogen-induced p21 expression at the
translational level (Gaben et al., 2004), as previously re-
ported for 5# oligopyrimidine (5# TOP) tract mRNAs,
such as eukaryotic elongation factor 1α (eEF-1α) (Fu-
magalli and Thomas, 2000). To test this, the effect of
RAD001 on the distribution of eEF-1α and β-actin
mRNAs was compared to that of p21 mRNA on sucrose
gradients from A549 tumor cells treated for 24 hr with
cisplatin. Under these conditions, eEF-1α mRNA relo-
cates from polysomes to nonpolysome fractions (Fig-
ure 7C), as previously shown for other cell types (Fuma-
galli and Thomas, 2000; Pende et al., 2004). Although
β-actin mRNA transcripts are normally not affected by
short-term rapamycin treatment (Fumagalli and Thomas,
2000; Pende et al., 2004), these longer exposure times
led to a significant portion relocating to the nonpoly-
some fractions (Figure 7C). Unexpectedly, the effect of
RAD001 on p21 mRNA distribution was less dramatic,
as only a minor portion appeared to shift to smaller
Cell
754Figure 7. RAD001 Blocks p21 Expression by Inhibition of Global Translation
(A) A549 cells were treated for 24 hr with 0.5 µg/ml cisplatin in the presence of DMSO or 20 nM RAD001, followed by cycloheximide for the
indicated times. Left panel, a representative experiment, in which actin and p21 protein levels were assessed by Western blotting. Right
panel, the fractional signal loss of p21 protein was determined using ImageQuant. The data represents the mean ± standard deviation of five
independent experiments. p21 half-life (t1/2) was calculated for each individual sample (n = 5) using nonlinear regression (one phase exponen-
tial decay). The differences between the t1/2 of DMSO- and RAD001-treated cells, 0.7 ± 0.1 hr and 0.5 ± 0.07 hr, respectively, was not
significant (p = 0.336; t test).
(B) After 24 hr, total RNA was isolated and p21, β-actin, and 18S RNA levels were assessed by Northern blot analysis with the indicated
probes from A549 cells treated with or without 0.5 µg/ml cisplatin in the presence of DMSO or 20 nM RAD001.
(C) A549 cells were treated for 24 hr with either 0.5 µg/ml cisplatin alone or in combination with 20 nM RAD001. Cell extracts were fractionated
on sucrose gradients and mRNAs encoding eEF-1α (top left panel), β-actin (bottom left panel), and p21 (right panel) located by Northern blot
analysis with the indicated probe.
(D) Northern blot and analysis of p21 mRNA located on polysome profiles displaying a more shallow gradient. ([C], right panel, and [D])
Gradient analysis of the polysome profiles of A549 cells treated 24 hr with 0.5 µg/ml cisplatin alone (black lines) or in combination with 20
nM RAD001 (gray lines).
(C and D) polysomes and (D) 40S subunits, 60S subunits, and 80S ribosomes are indicated.polysomes, an effect which roughly paralleled the e
ogeneral decrease in mean polysome size and the pro-
portion of ribosomes engaged in translation (Figure o
t7C). Note that the first polysome peak represents a di-
some with two 80S ribosomes bound to a single mRNA. s
cThe shift to nonpolysomes was more difficult to access
for p21 mRNA as the mean polysome size is w3 versus t
aw8 to 12 for eEF-1α and β-actin mRNAs (Figure 7C).
However, this shift was more evident, as was the de- g
lcrease in the mean polysome size of p21 transcripts
fromw3 tow2, when the analysis was performed using p
ta shallower sucrose gradient (Figure 7D). Moreover, thisffect is not specific to cisplatin-induced p21, as we
bserve a similar reduction of p21 protein and a shift
f p21 mRNA onto smaller polysomes in MCF7 cells
reated with RAD001 alone (Figure 4 and data not
hown). The results indicate that RAD001-induced de-
rease in p21 protein levels is not due to a selective
ranslational effect, as previously predicted (Gaben et
l., 2004), but to a small but significant decrease in
lobal translation, combined with the short half-life and
ow abundance of p21. Consequently, unlike highly ex-
ressed and stable housekeeping proteins, such as ac-
in, p21 protein decreases in the presence of RAD001
RAD001 Sensitization of Cisplatin-Induced Apoptosis
755facilitating an apoptotic response. This observation is
in line with the effects of other translational inhibitors,
e.g., cycloheximide, which have pronounced effects on
proteins with a short half-life, an effect that could
translate into a large therapeutic advantage.
Discussion
DNA-damaging agents, such as cisplatin, have had a
major impact on the treatment of a wide range of tumor
types (Siddik, 2003), although cisplatin’s use is limited
by cytotoxic side effects (Weiss, 2003). However, the
key concern is its narrow therapeutic window: too high
a dose is cytotoxic and too low a dose allows for DNA
repair (Weiss, 2003). Here, we provide evidence that the
use of RAD001 may increase this therapeutic window
by acting as a sensitizer for cisplatin-induced apopto-
sis due to its ability to block p53-induced p21 expres-
sion (Figures 4, 5, and 7). Consistent with these find-
ings, there is a positive correlation between wt p53
status and sensitivity to cisplatin (Fan et al., 1994;
Segal-Bendirdjian et al., 1998), a finding in line with the
significantly higher 5-year survival rate in cisplatin-
treated patients with wt p53 tumors (Siddik, 2003). The
capacity of cisplatin to trigger p53 expression is
thought to be primarily due to its ability to form DNA-
protein and DNA-DNA intrastrand crosslinks, which
act as apoptotic signals, triggering the activation of
DNA damage surveillance mechanisms (Siddik, 2003).
Whereas minimal DNA damage results in the initiation
of a DNA repair program by induction of cell cycle pro-
gression inhibitors such as p21 and GADD45α, exten-
sive DNA damage results in the induction of a proapo-
ptotic program, involving mediators such as PUMA,
NOXA, BAX, and PIG3 (Vousden and Lu, 2002). Consis-
tent with this, we find that at low cisplatin concentra-
tions p53 induces p21 with no apparent effect on cell
viability or PARP cleavage, whereas at high cisplatin
concentrations p53 induction of p21 is suppressed
(Figures 1 and 6). Myc induction is one mechanism by
which the p53 DNA damage response favors apoptosis
(Nilsson and Cleveland, 2003; Vousden, 2002), with Myc
being selectively recruited to the p21 promoter and se-
lectively suppressing p53-mediated p21 transcription
(Seoane et al., 2002; Wu et al., 2003). Cleavage of p21
by caspase 3 has also been shown to tilt the DNA dam-
age response toward apoptosis (Gervais et al., 1998;
Zhang et al., 1999). Whether similar mechanisms are
exploited by p53 as a function of the extent of DNA
damage caused by cisplatin has yet to be described.
The rapamycin derivatives RAD001 and CCI-779 are
currently being assessed in the treatment of advanced
cancer patients. Preclinical studies indicate that they
are potent inhibitors of tumor cell proliferation in vitro
and in animal models of cancer (Boulay et al., 2004;
Huang and Houghton, 2003; Majumder et al., 2004;
Wendel et al., 2004). Furthermore, such data show that
they are well tolerated (Dutcher, 2004), consistent with
the fact that in general rapamycins are cytostatic (Fig-
ures 1, 3, and 5), leading to the accumulation of cells in
G1 (Decker et al., 2003; Luan et al., 2002; Owa et al.,
2001). However, it has been reported that rapamycin
alone will induce apoptosis in p53-deficient cells stressedby extended serum depletion (Huang et al., 2001). In
this case, rapamycin induces sustained activation of
apoptosis regulated protein kinase 1 (ASK-1), resulting
in hyper-phosphorylation of c-Jun and apoptosis. This
effect is abrogated by ectopic overexpression of p21,
with p21 binding to ASK-1 and blocking JNK activation
(Huang et al., 2003b). It is speculated that these effects
are triggered by rapamycin-induced 4E-BP1 dephos-
phorylation, leading to either the activation or suppres-
sion of an ASK-1 phosphatase. This represents a
unique case of cellular stress quite distinct from DNA
damage, as underlined by the requirement of wt p53,
rather than its absence or mutation, in sensitizing tumor
cells to cisplatin-induced apoptosis (Figures 1, S2A,
and S2B). Although both paradigms involve the loss of
p21, the observations presented here underscore the
importance of the genetic makeup of the tumor in es-
tablishing strategies for combination therapies.
That rapamycin treatment leads to G1 accumulation
of cells is consistent with the fact that the drug inhibits
global translation and ribosome biogenesis, in part
through blocking the phosphorylation of S6K1 and 4E-
BP1 (Hay and Sonenberg, 2004). That these effects are
through inhibition of mTOR is demonstrated by altering
the rapamycin binding site, which protects S6K1 and
4E-BP1 from dephosphorylation as well as protects
cells from the antiproliferative effects of RAD001 and
its potentiation of apoptosis induced by cisplatin (Fig-
ures 2 and 3). The studies presented here also suggest
that these effects are mediated through inhibiting p21
protein expression, an effect that was first described in
T cells stimulated by IL2 (Nourse et al., 1994) and more
recently in mouse fibroblasts stimulated by insulin and
IGF-1 (Gaben et al., 2004). The induction of p21 in these
settings, unlike that for DNA damage, is required to fa-
cilitate the assembly of active cyclin D1/CDK4 com-
plexes (Cheng et al., 1999; LaBaer et al., 1997). In con-
trast, the upregulation of p53-induced p21 expression
in response to cisplatin (Figures 1 and 4–7) inhibits the
activity of G1 cyclin/CDK complexes, leading to cell cy-
cle arrest (Bartek and Lukas, 2001). p21 has also been
shown to attenuate cell cycle progression by binding
and sequestering PCNA, an essential component of the
DNA replication machinery (Li et al., 1994). By arresting
cell cycle progression, p21 prevents the onset of the
apoptotic program. In addition, p21 also acts to inhibit
proapoptotic components, such as procaspase 3, cas-
pase 8, and ASK-1 (Gartel and Tyner, 2002; Huang et
al., 2003b). For example, p21 binds to the amino termi-
nus of procaspase 3, protecting it from proteolytic
cleavage (Suzuki et al., 1998). Consistent with this, we
show that reduction of p21 in cells treated with low con-
centrations of cisplatin, by either RAD001 or siRNAs spe-
cific for p21, enhances PARP cleavage (Figures 5 and
6). These findings are supported by studies showing
that cells lacking p21 or treated with p21 antisense dis-
play enhanced sensitivity toward apoptosis induced by
DNA-damaging agents (Fan et al., 1997; Tian et al.,
2000), whereas tumors expressing high levels of p21
are prone to be resistant to DNA-damaging agents
(Kralj et al., 2003; Liu et al., 2004). Thus, induction of
p21 by low concentrations of cisplatin prevents apo-
ptosis by arresting cell cycle progression and inhibiting
proapoptotic factors.
Cell
756That rapamycin had no effect on mitogen-induced o
p21 mRNA levels or half-life led Gaben et al. (2004) to t
hypothesize that the drug lowers p21 levels through se- t
lective inhibition of its translation (Gaben et al., 2004), b
as has been observed for 5# TOP mRNAs (Fumagalli e
and Thomas, 2000; Pende et al., 2004). Here we show t
at 0.5 g of cisplatin that RAD001 does not affect the a
half-life, transcription, or translation of p21 in a selec- t
tive manner (Figure 7). Importantly, this does not ap- a
pear to be particular to cisplatin-induced p21, as we a
observe a similar reduction of p21 protein and a small f
but significant shift of p21 mRNA onto smaller poly- a
somes in nutrient-replete MCF7 cells treated with t
RAD001 alone (Figure 4 and data not shown). Thus, the i
general inhibition of translation and ribosome biogene- a
sis over this extended period leads to a small but im- w
portant shift of p21 transcripts to the nonpolysome s
fraction and to polysomes of smaller mean size (Figure a
7). This combined with the fact that p21 protein does g
not accumulate to high amounts and has a short half- s
life triggers an initial decrease in p21 protein levels a
shifting the equilibrium toward apoptosis. This obser- d
vation is consistent with the inherent definition of pro- t
teins with short-half lives, i.e., inhibition of general pro- w
tein synthesis leads to their selective and rapid s
decrease. However, it should be noted that as we raise r
the concentration of cisplatin and the apoptotic re- a
sponse ensues, we find that p21 mRNA levels decrease c
(data not shown), which may be due to the selective a
inhibition of p21 transcription as cells commit to apo- t
ptosis (Seoane et al., 2002). It should also be noted that m
the effect of RAD001 on global translation appears to c
be at the level of initiation, not elongation, as there is R
no increase in the mean polysome size (Figure 7C), nor t
do we observe a difference in elongation factor 2 phos- a
phorylation (data not shown), a known rapamycin- a
induced response reported to inhibit elongation (Proud,
2004). That a decrease in initiation of translation has a
Elarger impact on proteins with short half lives, such as
p21, versus those of high copy number is most evident
Cin comparing the distribution of actin transcripts and
A
actin protein. Whereas a large portion of actin mRNA 2
relocates to nonpolysomes in the presence of RAD001 P
(Figure 7C), there is no measurable change in actin pro- c
gtein levels (Figure 7A) due to its abundance and long
Mhalf-life. Recent studies have demonstrated the impor-
gtance of translational control in the cancer setting (Ra-
ajasekhar et al., 2003), effects which were largely as-
1
sumed to be selective (McCormick, 2004; Prendergast, v
2003). However, the changes in p21 protein levels re- m
ported here would not have been detected by analysis i
Sof the transcriptome or mRNAs associated with poly-
Dsomes (Rajasekhar et al., 2003), underscoring the im-
portance of global translation and the proteome.
The development of agents, which lower p21 protein S
levels, has been championed as an attractive approach w
to sensitize tumor cells to chemotherapeutic agents H
a(Weiss, 2003). However, with the exception of antisense
Roligodeoxynucleotides (Weiss et al., 2003), no pharma-
acological agents have arisen which directly attenuate
c
p21 protein expression (Weiss et al., 2003). The data f
presented here demonstrate that RAD001-induced down- 0
regulation of p21 results in enhanced apoptosis in the t
wpresence of suboptimal cisplatin concentrations. More-ver, p21 is only upregulated at low concentrations of
he DNA-damaging agent (Figure 6A), in part explaining
he gradual loss of enhancement when RAD001 is com-
ined with higher doses (Figure 1B). These results may
xplain the molecular basis of a recent study showing
hat rapamycin synergizes with doxorubicin to induce
poptosis in a mouse lymphoma model driven by ec-
opic expression of an activated PKB cDNA (Wendel et
l., 2004). In this system, the effect of rapamycin on
poptosis is bypassed by overexpressing initiation
actor 4E (eIF4E). This is consistent with the authors’
ssumption that activated PKB drives mTOR activa-
ion, which in turn phosphorylates 4E-BP1, relieving its
nhibitory effect on eIF4E (Hay and Sonenberg, 2004)
nd protecting tumors from apoptosis. From our data,
e would predict that overexpression of eIF4E in their
ystem drives global translation, increasing p21 levels
nd overriding the inhibitory effects of rapamycin on
lobal translation (Figure 7). Despite these potential
imilarities, these systems are quite distinct. Wendel et
l. (2004) were examining a defined set of tumors (Wen-
el et al., 2004) that are protected from apoptosis by
he ectopic expression of activated PKB. In contrast,
e set out to identify a mechanism by which RAD001
ensitizes tumor cells harboring multiple genetic aber-
ations to low concentrations of a DNA-damaging
gent. Indeed, p21 is induced at low concentrations of
isplatin where we observe no measurable effect on
poptosis or activation of PKB (data not shown). Taken
ogether, the preliminary findings in preclinical mouse
odels combined with the results presented here indi-
ate that in the clinic, targeting mTOR with agents like
AD001 may offer the opportunity to treat p53 wild-
ype tumors with much lower doses of DNA-damaging
gents, thereby reducing side effects while maintaining
ntitumor efficacy.
xperimental Procedures
ell Culture and Pharmacological Inhibitors
549 (CCL-185), Bing (CRL-1154), MCF7 (HTB-22), HCT-15 (CCL-
25), and DU145 (HTB-81) were from ATCC, Rockville, Maryland.
C3M cells were from J. Fidler. A549, Bing, and DU145 cells were
ultured in RPMI 1640 with 10% v/v fetal calf serum (FCS), 2 mM
lutamine, and 100 µg/ml penicillin/streptomycin. MCF7, P53+/+
EFS, and p53−/− MEFS were cultured in Dulbecco’s Modified Ea-
le’s Medium (DMEM) with 10% v/v FCS, 0.8 µg/ml bovine insulin,
nd 2 mM glutamine. PC3M cells were cultured in MEM-EBS with
0% v/v FCS, 2 mM glutamine, 1% nonessential amino acids, 1%
/v sodium pyruvate, and 2% v/v MEM vitamines. RAD001 (Everoli-
us, Novartis) was prepared as a 20 mM stock solution dissolved
n DMSO and stored at −20°C. Cisplatin (Platinol, Bristol-Myers
quibb) and Gemcitabine (Gemzar, Eli Lilly) were dissolved in
MSO as 10 mM stock solutions and stored at −20°C.
table Cell Lines
t and RR HA-mTOR cDNAs were obtained by digestion of pRK5/
A-mTOR with NruI/HindIII. Purified fragments were blunt-ended
nd cloned into the SnaBI site of the pBabe Puro retroviral vector.
etroviruses were obtained by transient transfection of the pack-
ging Bing cells with the indicated retroviral vectors using the
alcium phosphate precipitation. In the first round, cells were in-
ected with virus encoding the ecotropic receptor and selected in
.75 mg/ml neomycin. In the second round, cell pools expressing
he ecotropic receptor were infected with pBabe Puro, HA-mTOR
t, or HA-mTOR RR followed by selection in 0.5 µg/ml puromycin.
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757YO-PRO and Proliferation Assays
For the YO-PRO assay (Idziorek, 1995 1742), cells were seeded at
2 × 103 to 10 × 103 cells/100 µl in 96-well plates and incubated for
24 hr with the indicated concentrations of gemcitabine, cisplatin,
RAD001, or the vehicle (DMSO). Cell proliferation and viability were
assessed as indicated. A549 clones were plated in triplicate at a
density of 3.8 × 104/60 mm and grown for 24 hr, before the medium
was replaced with either the vehicle (DMSO) alone or RAD001 and
cells were grown for an additional 96 hr. Cell numbers were normal-
ized to the vehicle. For IC50 values, cells were seeded in triplicate
at 1.5 × 103/100 µl in 96-well plates. After 24 hr, the medium was
replaced with medium containing vehicle alone or RAD001, and the
cells were incubated for an additional 72 hr.
siRNA
A549 cells were plated at 0.1 × 106/60 mm plate. Five microliters of
twenty micromolar siRNA targeting either human p21 (Accession
number, or AN: NM000389; sequence: 5#-GTG GAC AGC GAG CAG
CTG A-3#), human p53 (AN: NM000546; sequence: 5#-GCA TCT TAT
CCG AGT GGA A-3#) or LacZ (AN: M55068; sequence: 5#-GCG GCT
GCC GGA ATT TAC CTT-3#) were mixed with 175 l Optimem
(Gibco, Cat. No.: 51985-026). In parallel, 8 l Oligofectamine (Invit-
rogen, Cat. No.: 12252-011) was mixed with 12 l Optimem. After
10 min incubation, the two solutions were mixed, incubated for 20
min, and 200 l was added to cells, which had been washed with
Optimem and then covered with an additional 1 ml of Optimem.
After 5 hr, the transfection mix was replaced with 5 ml RPMI 1640
containing 10% FCS. Cells were incubated for an additional 25 hr,
cisplatin added for 24 hr, and cell lysates prepared as below.
Biochemical Analysis of Apoptosis
Cells were seeded at 0.1–0.4 × 106/60 mm, incubated for 24 hr, and
treated as indicated in the text. Both floating and adherent cells
were collected by centrifugation, the supernatant removed, and 5
ml ice-cold phosphate-buffered saline (PBS) containing 0.1 mM
PMSF was added. After washing the cells a second time under the
same conditions, the cell pellet was resuspended in 60 µl extrac-
tion buffer containing 120 mM NaCl, 50 mM Tris (pH 8), 20 mM
NaF, 1 mM benzamidine, 1 mM EDTA, 1 mM EGTA, 15 mM tetra-
sodiumdiphosphate-decahydrate, 30 mM 4-nitrophenylphosphate
disoudium salt hexahydrate, 1 mM PMSF, 1 mM DTT, and 1% NP-
40. Cell lysates were prepared by pipetting the extract up and down
several times, cleared by centrifugation, snap frozen in liquid nitro-
gen, and stored at −80°C.
p21 Half-Life Determination
After 24 hr, A549 cells seeded at 0.5 × 106/10cm were treated with
either 0.5 µg/ml cisplatin alone or together with 20 nM RAD001,
then incubated for an additional 24 hr followed by treatment with
10 g/ml of cycloheximide for the indicated times. Cell extracts
were analyzed on Western blots.
Immunological Techniques
Western blots were performed as described (Boulay et al., 2004),
with the following antibodies: anti-mTOR (2972), -phospho-S6K1
Thr389 (9205), -phospho-S6 Ribosomal Protein Ser240/244
(2215), -PARP (9542) obtained from Cell Signaling Technology, -p53
(FL-393) (sc-6243, Santa Cruz Biotechnology, Santa Cruz, Cali-
fornia), -Bax (554104, Pharmingen), -p21 (EA10) (OP64, Onco-
gene), -S6 (Novartis), -4E-BP1 (N. Sonenberg, McGill University),
-pan actin (MAB1501, Chemicon International, Temecula, Cali-
fornia).
Analysis of mRNA
Preparation of cell extracts, gradient centrifugation, fractionation
of polysome profiles, and analysis by Northern blot were done as
described (Pende et al., 2004). To obtain polysome profiles with a
more shallow gradient, 500 g of extract was applied to a 5.1%–
41% sucrose gradient and centrifuged in a SW41 rotor at 40,000
rpm for 2 hr at 4°C. Analysis and fractionation of polysome profiles
were done using an UA-6 detector from ISCO.Radioactive Labeling of Probes
The p53, p21, eEF-1α, β-actin, and 18S rRNA oligonucleotide
probes were complementary to nucleotides: 1 to 1181 of the human
p53 cDNA (AN: NM000546), 568 to 724 of the human p21cDNA (AN:
NM000389), 51 to 112 of the mouse eEF-1α cDNA (AN: X13661),
121 to 179 of the mouse β-actin cDNA (AN: X03765), and 4656 to
4685 of the mouse 45 rRNA (AN: BK000964). Probes were labeled
as previously described (Pende et al., 2004).
Satistical Analyses
Where possible, data are presented as means ±1 standard devia-
tion. Statistical evaluations were carried out using SigmaStat 2.03
(SPSS, San Rafael, California), and curve-fitting utilized GraphPad
Prism 3.02 (GraphPad Software Inc., San Diego, California). For all
tests, the level of statistical significance was set at p < 0.05. When
needed, data were transformed to achieve a normal distribution.
For the cell proliferation and YO-PRO assays, t tests or Rank sum
tests were used. Two-way ANOVA was used to determine the sta-
tistical significance of any possible interaction of cisplatin and
RAD001. One-way ANOVA was used to analyze dose effects of
RAD001. Determination of the half-life of p21 decay utilized nonlin-
ear regression assuming one-phase exponential decay. Applicabil-
ity of this regression was assured by Goodnesss of Fit and Runs
tests.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/cgi/content/full/120/6/747/
DC1/.
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